drugset / Trial / NCT05387317
Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)
Phase 3
Withdrawn
Murdoch Childrens Research Institute
Coalition for Epidemic Preparedness Innovations · collabIndonesia University · collabNational Institute of Health Research and Development, Ministry of Health Republic of Indonesia · collabThe Peter Doherty Institute for Infection and Immunity · collabUniversitas Padjadjaran · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a randomised controlled clinical trial to determine the reactogenicity and immunogenicity of booster doses of SARS-CoV-2 vaccines (Pfizer-BioNTech, AstraZeneca or Moderna) in adults who have previously received either AstraZeneca or Coronavac as their primary doses. Both fractional and standard doses of Pfizer-BioNTech, AstraZeneca and Moderna will be tested.
Timeline
- Start
- 2024-04
- Primary completion
- 2025-01
- Completion
- 2025-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BNT162b2 | Messenger RNA (mRNA) | 15 ug | — |
| Subject | BNT162b2 | Messenger RNA (mRNA) | 30 ug | — |
| Subject | Bupivacaine | Other / unclassified | 2.5e+10 unknown | — |
| Subject | Bupivacaine | Other / unclassified | 5e+10 unknown | — |
| Subject | Elasomeran | Messenger RNA (mRNA) | 20 ug | — |
| Subject | Elasomeran | Messenger RNA (mRNA) | 50 ug | — |